-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A simple blood test to diagnose Alzheimer's disease is an exciting possibility, perhaps even years before symptoms appear, but a new study suggests that before these blood tests are routinely used in clinical diagnostic settings , more research is need.
The research is published in the latest online edition of Nature Medici.
Two hallmarks of Alzheimer's disease are tau tangles and beta-amyloid plaqu.
"Blood biomarkers are targets for screening and diagnosis of Alzheimer's disease because they are less expensive and more invasive, but we need to understand these biomarkers in community populations before they can be used clinical.
Phosphorylated tau181 and 217 (p-tau181 and p-tau217), two blood markers, are expected to be new specific biomarkers for Alzheimer's disease and may provide new insights into the screening or detection of Alzheimer's disease in the general population w.
"Before these blood-based biomarkers enter clinical use, it is critical that we establish reference ranges that understand differences in age, sex and underlying health conditio.
In the study, researchers tested 1,329 participants, ages 30 to 98, with p-tau181 and p-tau217 through the Mayo Clinic study of Aging to assess the effects of PET imaging on Diagnostic role of p-tau181 and p-tau217, which are predictors of elevated brain beta-amyloid and tau tangl.
The researchers found that while p-tau181 and p-tau217 increased with age, the increase occurred primarily in people who were amyloid-positive, suggesting that these biomarkers are specific for Alzheimer's disease rather than Other neurodegenerative diseases provide additional eviden.
The study's findings also confirmed that plasma p-tau181 and p-tau217 were predictors of elevated brain amyloid and tau, as measured by PET imaging, but the results were not as good as reported by patients previously seen in specialized memory clinics Go.
"More research needs to be done in larger studies, especially in more diverse populations," Milk sa.